Celularity appoints Andrew Pecora as President; Hariri remains CEO and Chairman

Celularity Inc

Andrew Pecora named President effective Sept 15, 2021, replacing Robert Hariri who stays CEO/Chairman.
Pecora receives $900K base salary, 60% target bonus, and a signing bonus of $1.2M paid in four installments.
Granted option to purchase 2,469,282 shares, vesting upon achievement of share price targets over up to five installments.
Pecora previously served as consultant and on Sci Advisory Board; related party transactions with COTA and son's employment disclosed.
Employment at-will; severance includes nine months' salary (or 12 months after change in control) and COBRA coverage.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew L. Pecora, M.D.

President

CELU · Celularity Inc

Effective: 2021-09-15
Filed: September 15, 2021, 7:59 PM ET

appointed Andrew L. Pecora, M.D., as President of the Company effective September 15, 2021, replacing Robert J. Hariri, M.D., Ph.D., in this role as of such date.

Role change

Robert J. Hariri, M.D., Ph.D.

Chief Executive Officer and Chairman of the Board

CELU · Celularity Inc

Effective: 2021-09-15
Successor: Andrew L. Pecora, M.D.
Filed: September 15, 2021, 7:59 PM ET

appointed Andrew L. Pecora, M.D., as President of the Company effective September 15, 2021, replacing Robert J. Hariri, M.D., Ph.D., in this role as of such date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Andrew L. Pecora, M.D. was appointed as President at Celularity Inc.

Action: appointed
Role: President

Exact text from the filing

appointed Andrew L. Pecora, M.D., as President of the Company effective September 15, 2021, replacing Robert J. Hariri, M.D., Ph.D., in this role as of such date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Robert J. Hariri, M.D., Ph.D. changed role as Chief Executive Officer and Chairman of the Board at Celularity Inc.

Action: replaced as President
Role: Chief Executive Officer and Chairman of the Board

Exact text from the filing

appointed Andrew L. Pecora, M.D., as President of the Company effective September 15, 2021, replacing Robert J. Hariri, M.D., Ph.D., in this role as of such date.

View on SEC.gov

Celularity Inc filing history →

Source: SEC EDGAR

accession 0001213900-21-048256

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.